Zota Health Care AGM: Approves 10% Final Dividend, Director Re-appointments
Zota Health Care's 26th AGM on Sep 28, 2026, approved the FY26 financial statements and a 10% final dividend (Re. 1/share). Key re-appointments included Kamlesh Rajanikant Zota and Moxesh Ketanbhai Zota. Mahaveer Dhariwal was appointed as Independent Director. Related party transactions were also approved.
The AGM outcome includes routine financial approvals, dividend declaration, and board appointments/re-appointments, which have a moderate impact on investor sentiment and company operations.
The company declared a dividend and re-appointed key management personnel, which are generally positive indicators for shareholders.
Zota Health Care Limited held its 26th Annual General Meeting (AGM) on September 28, 2026, at 11:00 AM IST, conducted via Video Conferencing (VC)/ Other Audio Visual Means (OAVM).
During the meeting, the members adopted the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. A final dividend of 10%, amounting to Re. 1 per equity share, was declared for the financial year 2025-26.
Key personnel decisions included the re-appointment of Mr. Kamlesh Rajanikant Zota as a Whole-time Director, the appointment of Mr. Mahaveer Dhariwal as an Independent Director, and the re-appointment of Mr. Moxesh Ketanbhai Zota as the Managing Director. The remuneration payable to Mr. Ketankumar Chandulal Zota, Non-Executive Chairman, was also approved. Furthermore, resolutions were passed concerning the approval of related party transactions, including remunerations to Directors and Senior Marketing Manager, and a material related party transaction with Everyday Herbal Beauty Care Limited, a subsidiary.
The AGM concluded at 11:32 AM, with e-voting closing at 11:47 AM. The voting results and the presentation delivered during the AGM will be submitted to the stock exchange and uploaded on the company's website.
What to do with a filing like this
Zota Health Care LImited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zota Health Care LImited. Read the original for the full detail.